PMID- 28119930
OWN - NLM
STAT- MEDLINE
DCOM- 20170522
LR  - 20190723
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2016
DP  - 2016
TI  - Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: 
      A Cohort Study.
PG  - 1423191
LID - 10.1155/2016/1423191 [doi]
LID - 1423191
AB  - Aims. Dipeptidyl-peptidase IV inhibitors (DPP-4i) are among the most popular oral 
      antidiabetic agents. However, the effects of DPP-4i on diabetic nephropathy are 
      not well-established. The aim of this study was to determine the renoprotective 
      effects of DPP-4i, using albuminuria and glomerular filtration rate (GFR) as 
      indicators, in type 2 diabetes mellitus (T2DM) patients. Methods. This 
      retrospective observational cohort study used the clinical database of a tertiary 
      hospital. The changes of urine albumin/creatinine ratio (UACR), estimated GFR 
      (eGFR), and metabolic parameters after treatment were compared with the changes 
      of those parameters before treatment using paired Student's t-test. Results. The 
      mean UACR in the entire study population decreased to approximately 45 mg/g 1 
      year after DPP-4i treatment, while it was increased approximately 39 mg/g 1 year 
      before DPP-4i treatment (p < 0.05). Patients with macroalbuminuria showed a 
      significant reduction in albumin levels after DPP-4i treatment (p < 0.05); 
      however, patients with microalbuminuria and normoalbuminuria did not show 
      improvements in albuminuria levels after treatment. Although eGFR was not changed 
      1 year after DPP-4i treatment, reductions in eGFR were slowed in patients with 
      microalbuminuria and reversed in the macroalbuminuria or normoalbuminuria groups, 
      4 years after treatment. Conclusions. Administration of DPP-4i reduces urine 
      albumin excretion and mitigates reduction of eGFR in T2DM patients.
FAU - Kim, Young-Gun
AU  - Kim YG
AUID- ORCID: 0000-0002-8982-5230
AD  - Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, 
      Republic of Korea.
FAU - Byun, JungHyun
AU  - Byun J
AD  - Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, 
      Republic of Korea.
FAU - Yoon, Dukyong
AU  - Yoon D
AD  - Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, 
      Republic of Korea.
FAU - Jeon, Ja Young
AU  - Jeon JY
AD  - Department of Endocrinology and Metabolism, Ajou University School of Medicine, 
      Suwon, Republic of Korea.
FAU - Han, Seung Jin
AU  - Han SJ
AD  - Department of Endocrinology and Metabolism, Ajou University School of Medicine, 
      Suwon, Republic of Korea.
FAU - Kim, Dae Jung
AU  - Kim DJ
AD  - Department of Endocrinology and Metabolism, Ajou University School of Medicine, 
      Suwon, Republic of Korea.
FAU - Lee, Kwan-Woo
AU  - Lee KW
AD  - Department of Endocrinology and Metabolism, Ajou University School of Medicine, 
      Suwon, Republic of Korea.
FAU - Park, Rae Woong
AU  - Park RW
AUID- ORCID: 0000-0003-4989-3287
AD  - Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, 
      Republic of Korea; Department of Biomedical Sciences, Ajou University Graduate 
      School of Medicine, Suwon, Republic of Korea.
FAU - Kim, Hae Jin
AU  - Kim HJ
AUID- ORCID: 0000-0002-8958-7164
AD  - Department of Endocrinology and Metabolism, Ajou University School of Medicine, 
      Suwon, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20161229
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Albumins)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Aged
MH  - Albumins/analysis
MH  - Albuminuria/drug therapy
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diabetic Nephropathies/prevention & control
MH  - Dipeptidyl Peptidase 4/*metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Kidney/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Models, Statistical
MH  - Retrospective Studies
PMC - PMC5228170
COIS- The authors declare no competing interests.
EDAT- 2017/01/26 06:00
MHDA- 2017/05/23 06:00
PMCR- 2016/12/29
CRDT- 2017/01/26 06:00
PHST- 2016/10/19 00:00 [received]
PHST- 2016/12/01 00:00 [revised]
PHST- 2016/12/12 00:00 [accepted]
PHST- 2017/01/26 06:00 [entrez]
PHST- 2017/01/26 06:00 [pubmed]
PHST- 2017/05/23 06:00 [medline]
PHST- 2016/12/29 00:00 [pmc-release]
AID - 10.1155/2016/1423191 [doi]
PST - ppublish
SO  - J Diabetes Res. 2016;2016:1423191. doi: 10.1155/2016/1423191. Epub 2016 Dec 29.